WO2000007621A3 - Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent - Google Patents

Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent Download PDF

Info

Publication number
WO2000007621A3
WO2000007621A3 PCT/EP1999/005587 EP9905587W WO0007621A3 WO 2000007621 A3 WO2000007621 A3 WO 2000007621A3 EP 9905587 W EP9905587 W EP 9905587W WO 0007621 A3 WO0007621 A3 WO 0007621A3
Authority
WO
WIPO (PCT)
Prior art keywords
saponin
iscom
sterol
vaccine
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/005587
Other languages
French (fr)
Other versions
WO2000007621A2 (en
Inventor
Martin Friede
Nathalie Garcon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to DE69935598T priority Critical patent/DE69935598T2/en
Priority to JP2000563304A priority patent/JP2002522397A/en
Priority to CA002339486A priority patent/CA2339486A1/en
Priority to US09/744,800 priority patent/US6506386B1/en
Priority to EP99941506A priority patent/EP1102600B1/en
Priority to AU55099/99A priority patent/AU738965B2/en
Publication of WO2000007621A2 publication Critical patent/WO2000007621A2/en
Publication of WO2000007621A3 publication Critical patent/WO2000007621A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides an improved adjuvant formulation and a process for producing said adjuvant. The adjuvant comprises an ISCOM structure comprising a saponin, said ISCOM structure being devoid of additional detergent.
PCT/EP1999/005587 1998-08-05 1999-08-03 Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent Ceased WO2000007621A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE69935598T DE69935598T2 (en) 1998-08-05 1999-08-03 VACCINE CONTAINS AN ISCOM CONSISTING OF STEROL AND SAPONINE AND FREE OF ADDITIONAL DETERGENTS
JP2000563304A JP2002522397A (en) 1998-08-05 1999-08-03 Vaccine containing ISCOM consisting of sterol and saponin without other surfactants
CA002339486A CA2339486A1 (en) 1998-08-05 1999-08-03 Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent
US09/744,800 US6506386B1 (en) 1998-08-05 1999-08-03 Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent
EP99941506A EP1102600B1 (en) 1998-08-05 1999-08-03 Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent
AU55099/99A AU738965B2 (en) 1998-08-05 1999-08-03 Vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9817052.5 1998-08-05
GBGB9817052.5A GB9817052D0 (en) 1998-08-05 1998-08-05 Vaccine

Publications (2)

Publication Number Publication Date
WO2000007621A2 WO2000007621A2 (en) 2000-02-17
WO2000007621A3 true WO2000007621A3 (en) 2000-06-02

Family

ID=10836763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/005587 Ceased WO2000007621A2 (en) 1998-08-05 1999-08-03 Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent

Country Status (10)

Country Link
US (1) US6506386B1 (en)
EP (1) EP1102600B1 (en)
JP (1) JP2002522397A (en)
AT (1) ATE357251T1 (en)
AU (1) AU738965B2 (en)
CA (1) CA2339486A1 (en)
DE (1) DE69935598T2 (en)
ES (1) ES2284265T3 (en)
GB (1) GB9817052D0 (en)
WO (1) WO2000007621A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339367B2 (en) 2009-09-28 2022-05-24 Glaxosmithkline Biologicals Sa Hyperblebbing Shigella strains

Families Citing this family (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
SI1077722T1 (en) 1998-05-22 2007-02-28 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
US20080077251A1 (en) * 1999-06-07 2008-03-27 Chen Silvia S Cleaning and devitalization of cartilage
US8563232B2 (en) 2000-09-12 2013-10-22 Lifenet Health Process for devitalizing soft-tissue engineered medical implants, and devitalized soft-tissue medical implants produced
NZ520976A (en) * 1999-11-19 2005-01-28 Csl Ltd Vaccine compositions
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
JP2004535765A (en) 2000-12-07 2004-12-02 カイロン コーポレイション Endogenous retrovirus up-regulated in prostate cancer
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
US20030224020A1 (en) * 2002-05-31 2003-12-04 Zabudkin Alexander F. Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ATE449612T1 (en) * 2002-10-02 2009-12-15 Nordic Vaccine Technology As COMPOSITION FOR VACCINATION
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2502015A1 (en) * 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
ES2505695T3 (en) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Immunogenic compositions for Streptococcus pyogenes
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP5600375B2 (en) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Influenza virus vaccine
KR20110132416A (en) * 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 Microfluidized Oil-in-water Emulsions and Vaccine Compositions
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
US20090053261A1 (en) * 2005-09-08 2009-02-26 Lindbo John A Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP2848692B1 (en) 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
EP2269638A3 (en) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
US20060287263A1 (en) * 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
JP2008508320A (en) 2004-07-29 2008-03-21 カイロン コーポレイション Immunogenic composition against gram positive bacteria such as STREPTOCOCCUSAGALACTIAE
US20070190072A1 (en) * 2004-09-30 2007-08-16 Csl Limited Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus adjuvant
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SI1858920T1 (en) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2008530245A (en) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Antigens from uropathogenic strains
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514844A (en) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Emulsions containing free aqueous phase surfactants as adjuvants for split influenza vaccines
ES2514316T3 (en) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
PL2478916T3 (en) 2006-01-27 2020-11-16 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
ES2536426T3 (en) 2006-03-23 2015-05-25 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CN101448523A (en) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 Storage of influenza vaccines without refrigeration
EP2382988A1 (en) 2006-03-31 2011-11-02 Novartis AG Combined mucosal and parenteral immunization against HIV
PT2054431E (en) 2006-06-09 2011-11-03 Novartis Ag Conformers of bacterial adhesins
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
SG179457A1 (en) 2006-12-01 2012-04-27 Anterios Inc Peptide nanoparticles and uses therefor
SG177184A1 (en) 2006-12-01 2012-01-30 Anterios Inc Amphiphilic entity nanoparticles
PT2121011E (en) 2006-12-06 2014-07-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2679720A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
US20110097360A1 (en) 2007-05-25 2011-04-28 Claudio Donati Streptococcus pneumoniae pilus antigens
CN101765423B (en) 2007-05-31 2014-08-06 安特里奥公司 Nucleic acid nanoparticles and uses thereof
KR20100045437A (en) 2007-06-27 2010-05-03 노파르티스 아게 Low-additive influenza vaccines
US20090024224A1 (en) 2007-07-16 2009-01-22 Chen Silvia S Implantation of cartilage
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN102356089B (en) 2008-02-21 2014-02-19 诺华股份有限公司 Meningococcal fHBP polypeptide
ES2325243B1 (en) 2008-02-27 2011-05-04 Universidad De Granada RECOMBINANT ANTIGEN.
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
JP5518041B2 (en) 2008-03-18 2014-06-11 ノバルティス アーゲー Improvements in the preparation of influenza virus vaccine antigens
BRPI0922561A2 (en) 2008-12-09 2020-08-11 Pfizer Vaccines Llc ige ch3 peptide vaccine.
CN103897045A (en) 2009-01-12 2014-07-02 诺华股份有限公司 Cna_b domain antigens in vaccines against gram positive bacteria
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
DK2442826T3 (en) 2009-06-15 2015-09-21 Univ Singapore Influenza vaccine, composition and methods of using
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
JP2013500326A (en) 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー Antigenic tau peptides and uses thereof
CN102596240B (en) 2009-08-27 2015-02-04 诺华股份有限公司 Hybrid polypeptides including meningococcal fHBP sequences
WO2011027257A2 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
BR112012009014B8 (en) 2009-09-30 2022-10-04 Novartis Ag PROCESS FOR PREPARING S. AUREUS CAPSULAR POLYSACCHARIDE CONJUGATE TYPE 5 OR TYPE 8 AND CRM197 TRANSPORT MOLECULE, CONJUGATE AND IMMUNOGENIC COMPOSITION
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
RU2581020C2 (en) 2009-12-22 2016-04-10 Селлдекс Терапьютикс, Инк. Vaccine compositions
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
DE102010013410A1 (en) 2010-03-30 2010-08-05 Reimer Offen Device for detection of fluid surface for positioning pipette needle below fluid surface in analysis machine, has thermal element attached at cone point of probe such that coolness of fluid is measured, during immersion of probe
TR201802933T4 (en) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland The modified factor h binding proteins (fhbp) and their method of use.
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2558069A1 (en) 2010-04-13 2013-02-20 Novartis AG Benzonapthyridine compositions and uses thereof
KR20130121699A (en) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 Interactive hybrid asynchronous computer game infrastructure
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
EP2472855A1 (en) * 2010-12-29 2012-07-04 Advanced Digital Broadcast S.A. Television user interface
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
EP2707025B8 (en) 2011-05-13 2017-08-23 Zoetis Services LLC Hendra and nipah virus g glycoprotein immunogenic compositions
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
DK2750683T4 (en) 2011-10-03 2021-04-12 Croda Int Plc NANOPARTICLES, METHODS OF THE MANUFACTURE AND USE THEREOF, WHICH CARRY FOR AMPIPATIC OR HYDROPHOBIC MOLECULES IN MEDICINES, INCLUDING CANCER TREATMENT, AND IN FOOD RELATIONS
EP4218808A3 (en) * 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvant and vaccine compositions
RU2014151567A (en) 2012-05-22 2016-07-10 Новартис Аг CONJUGATE MENINGOCOCCA SEROGRAPH X
US20150140068A1 (en) 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
JP6283674B2 (en) 2012-09-18 2018-02-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Outer membrane vesicles
TR201808684T4 (en) 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Nonlinear saccharide conjugates.
RU2015106791A (en) 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са IMMUNOGENIC COMPOSITIONS
CN111249455A (en) 2012-11-30 2020-06-09 葛兰素史密丝克莱恩生物有限公司 Pseudomonas antigens and antigen combinations
UY34506A (en) 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa VACCINATION ASSISTANT, PREPARATION AND VACCINES CONTAINING IT
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
JP2016520077A (en) 2013-05-15 2016-07-11 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ E1E2HCV vaccine and method of use
MX2016007870A (en) 2013-12-16 2016-10-07 Zoetis Services Llc Hendra and nipah virus g glycoprotein immunogenic compositions.
CN110859957B (en) 2014-01-21 2024-04-12 辉瑞公司 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
AU2015236106A1 (en) * 2014-03-25 2016-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (MPLA)-containing liposome composition and a saponin
CN106103469B (en) 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 mutant staphylococcal antigen
KR102761870B1 (en) 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 Factor h binding protein variants and methods of use thereof
HUE062499T2 (en) 2015-01-15 2023-11-28 Pfizer Immunogenic compositions for use in pneumococcal vaccines
US10576131B2 (en) 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
US20180186896A1 (en) 2015-07-07 2018-07-05 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
KR102225282B1 (en) 2015-07-21 2021-03-10 화이자 인코포레이티드 Immunogenic composition comprising conjugated capsular saccharide antigen, kit comprising same, and use thereof
CN107921113A (en) 2015-08-25 2018-04-17 巴比塔·阿格拉沃尔 Immunomodulatory compositions and methods of use thereof
EP4491735A3 (en) 2015-10-08 2025-04-16 The Governors of the University of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
JP6884145B2 (en) 2015-11-20 2021-06-09 ファイザー・インク Immunogenic composition for use in Streptococcus pneumoniae vaccine
MX2019005833A (en) 2016-11-21 2019-10-30 Eirion Therapeutics Inc Transdermal delivery of large agents.
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
BR112019014833A2 (en) 2017-01-20 2020-04-14 Pfizer immunogenic compositions for use in pneumococcal vaccines
BR112019025104A2 (en) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. METHOD OF MANUFACTURING A NON-VIRAL DELIVERY SYSTEM, NON-VIRAL DELIVERY SYSTEM, AND, COMPOSITION
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
EP3840770A1 (en) 2018-08-23 2021-06-30 GlaxoSmithKline Biologicals SA Immunogenic proteins and compositions
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020097923A1 (en) 2018-11-16 2020-05-22 The University Of Hong Kong Live attenuated influenza b virus compositions methods of making and using thereof
EP3886901A1 (en) * 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP4021407A1 (en) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Jet mixing lipid nanoparticle manufacturing process
US20230000966A1 (en) 2019-11-01 2023-01-05 Pfizer Inc. Escherichia coli compositions and methods thereof
CN113134079A (en) * 2020-01-17 2021-07-20 武汉戴安生物技术有限公司 Immunologic adjuvant for neutralizing antibody
NL2030835B1 (en) 2020-01-24 2022-12-29 Aim Immunotech Inc Methods, compositions, and vaccinces for treating a virus infection
CN119371566A (en) 2020-02-21 2025-01-28 辉瑞公司 Purification of saccharides
BR112022014555A2 (en) 2020-02-23 2022-09-20 Pfizer COMPOSITIONS OF ESCHERICHIA COLI AND METHODS THEREOF.
WO2021169673A1 (en) 2020-02-26 2021-09-02 Versitech Limited Pd-1-based vaccines against coronavirus infection
PE20231934A1 (en) 2020-10-27 2023-12-01 Pfizer COMPOSITIONS OF ESCHERICHIA COLI AND METHODS THEREOF
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
JP7804673B2 (en) 2020-11-10 2026-01-22 ファイザー・インク Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
JP2024521847A (en) 2021-05-28 2024-06-04 ファイザー・インク Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2023013434A (en) 2021-05-28 2023-12-12 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof.
US20250302943A1 (en) 2021-11-05 2025-10-02 King Abdullah University Of Science And Technology Re-focusing protein booster immunization compositions and methods of use thereof
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
US20250049899A1 (en) 2021-11-18 2025-02-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CA3256617A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024107474A1 (en) * 2022-11-15 2024-05-23 Massachusetts Institute Of Technology Controlled lipid self-assembly for scalable manufacturing of next-generation immune stimulating complexes
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4622665A2 (en) 2022-11-22 2025-10-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2023403045A1 (en) 2022-12-01 2025-06-12 Pfizer Inc. Pneumococcal conjugate vaccine formulations
EP4633671A1 (en) 2022-12-14 2025-10-22 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20252774A1 (en) 2023-03-30 2025-12-22 Pfizer IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011711A1 (en) * 1994-10-12 1996-04-25 Iscotec Ab Saponin preparations and use thereof in iscoms
US5620690A (en) * 1990-10-23 1997-04-15 De Stat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn Volksgezondheid En Cultuur Immunogenic complexes
US5679354A (en) * 1988-09-30 1997-10-21 Morein; Bror Matrix with immunomodulating activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679354A (en) * 1988-09-30 1997-10-21 Morein; Bror Matrix with immunomodulating activity
US5620690A (en) * 1990-10-23 1997-04-15 De Stat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn Volksgezondheid En Cultuur Immunogenic complexes
WO1996011711A1 (en) * 1994-10-12 1996-04-25 Iscotec Ab Saponin preparations and use thereof in iscoms

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARR I G ET AL: "ISCOMs (immunostimulating complexes): the first decade.", IMMUNOLOGY AND CELL BIOLOGY, (1996 FEB) 74 (1) 8-25. REF: 152, XP002128950 *
KERSTEN G F ET AL: "On the structure of immune-stimulating saponin -lipid complexes iscoms ).", BIOCHIMICA ET BIOPHYSICA ACTA, (1991 FEB 25) 1062 (2) 165-71., XP002128948 *
SJOLANDER, ANDERS ET AL: "Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines", ADV. DRUG DELIVERY REV. (1998), 34(2,3), 321-338, XP002128949 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339367B2 (en) 2009-09-28 2022-05-24 Glaxosmithkline Biologicals Sa Hyperblebbing Shigella strains

Also Published As

Publication number Publication date
US6506386B1 (en) 2003-01-14
EP1102600B1 (en) 2007-03-21
DE69935598T2 (en) 2007-11-29
ES2284265T3 (en) 2007-11-01
WO2000007621A2 (en) 2000-02-17
DE69935598D1 (en) 2007-05-03
AU738965B2 (en) 2001-10-04
EP1102600A2 (en) 2001-05-30
GB9817052D0 (en) 1998-09-30
CA2339486A1 (en) 2000-02-17
ATE357251T1 (en) 2007-04-15
AU5509999A (en) 2000-02-28
JP2002522397A (en) 2002-07-23

Similar Documents

Publication Publication Date Title
WO2000007621A3 (en) Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent
AU2001240115A1 (en) Method for the preparation of tetrahydrobenzothiepines
AU2001290295A1 (en) Crystalline mww-type titanosilicate , its preparation and use thereof for producing epoxides
AU7881400A (en) Assembly process for delicate silicon structures
AU2001252588A1 (en) Method for preparing microsphere
ZA200110179B (en) Process for the preparation of pure citalopram.
AU2001295939A1 (en) Process for preparation of polyisocyanate composition
MXPA03001800A (en) Process for the preparation of substituted phenylacetonitriles.
AU2001273762A1 (en) Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols
SI1325022T1 (en) Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)
AU2001291871A1 (en) Method for the isomerisation of allyl alcohols
ITRM20000266A0 (en) IMPROVED PROCESS FOR THE PREPARATION OF (E,Z) 3-(2-AMINOETHOXYMINO)-ANDROSTAN-6, 17-DION AND ITS ANALOGUES.
WO2002017961A1 (en) Vaccine preparation containing fatty acid as component
HK1051356A1 (en) Calcilytic compounds
AU2002330042A1 (en) Process for the preparation of 1,5-diarylpyrazoles
AU2001248998A1 (en) Method for the preparation of (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1- naphthalenemethanamine (terbinafine)
AU2002214954A1 (en) Process for the preparation of phenylphenol compounds
WO2002034204A8 (en) Calcilytic compounds
AU2002229648A1 (en) A process for the preparation of citalopram
AU2827100A (en) Process for the preparation of phenylhydrazines
AU2000261768A1 (en) An improved process for the preparation of docetaxel
AU2001277801A1 (en) Process for preparing 2,3-diaminopropanols and synthesis of other compounds using 2,3-diaminopropanols
AU5462901A (en) Process for the preparation of (pyridinylidene)-phthalides
AU4428700A (en) High purity 4,4-isopropylidene-bis-(2,6 dibromophenol) and process for the preparation of such high purity 4,4-isopropylidene-bis-(2,6 dibromophenol)
AU2000279379A1 (en) An improved process for the preparation of 10h-phenoxazine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 55099/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2339486

Country of ref document: CA

Ref country code: CA

Ref document number: 2339486

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999941506

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999941506

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09744800

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 55099/99

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1999941506

Country of ref document: EP